Vertex Pharmaceuticals Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +3.07%.
Did VRTX Beat Earnings? Q2 2025 Results
Vertex Pharmaceuticals posted a confident beat to open its second quarter, with non-GAAP earnings of $4.52 per share clearing the $4.25 consensus by 6.33% and revenue of $2.96 billion topping estimates by 2.00% on 12.1% year-over-year growth, adding to <a href="https://247wallst.com/investing/2025/07/21/stock-market-live-july-21-sp-500-voo-inches-higher-on-more-good-earnings-news/">a broader run of strong earnings</a> across the market. The primary engine remained the cystic fibrosis franchise, where TRIKAFTA/KAFTRIO contributed $2.55 billion, while next-generation modulator ALYFTREK added $156.80 million in its first full ramp quarter following approvals in the U.S., EU, U.K., and Canada. CASGEVY and newly launched JOURNAVX provided incremental contributions as those programs build commercial momentum. The quarter was not without setbacks; VX-993 failed its Phase 2 primary endpoint in acute pain, and the FDA signaled a narrow path for broad peripheral neuropathic pain labeling. Still, Vertex reiterated its full-year 2025 revenue guidance of $11.85 billion to $12.00 billion, underpinned by continued CF growth and advancing pipeline catalysts, including povetacicept and zimislecel regulatory submissions expected in 2026.
- Continued performance of CF therapies including TRIKAFTA/KAFTRIO
- Early contributions from ALYFTREK, CASGEVY, and JOURNAVX launches
- Strong U.S. patient demand and favorable gross-to-net dynamics versus prior year
- Strong performance across multiple geographies outside the U.S.
“Vertex delivered a strong quarter of revenue growth with each of our three product launches — ALYFTREK, JOURNAVX, and CASGEVY — contributing, as well as continued advancement of our clinical programs. As we enter the second half of the year, we are focused on expanding leadership in cystic fibrosis, executing the launches, advancing the pipeline, and preparing for submissions and commercialization in additional disease areas.”
Vertex Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Vertex reiterated its full-year 2025 financial guidance: total revenue of $11.85 billion to $12.0 billion, assuming continued CF growth including the global ALYFTREK launch, continued CASGEVY uptake, and early JOURNAVX contributions. Combined GAAP R&D, AIPR&D and SG&A expenses are guided at $5.55 to $5.7 billion; combined non-GAAP at $4.9 to $5.0 billion, including approximately $100 million of AIPR&D expenses. Non-GAAP effective tax rate is guided at 20.5%-21.5%. The company noted an immaterial tariff cost impact for 2025 and does not expect the recent U.S. tax legislation (H.R.1) to materially change its non-GAAP effective tax rate.
VRTX YoY Financials
VRTX Revenue by Segment
VRTX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.